神経疾患治療薬の世界市場レポート 2025年

神経疾患治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は6.2%で、1,146億5,000万米ドルに成長します。予測期間の成長は、治療選択肢の拡大と個別化治療、疾患修飾治療への注目の高まり、デジタルバイオマーカーの利用拡大、神経疾患の有病率の増加などに起因すると考えられます。予測期間における主な動向としては、薬剤設計の進歩、神経画像診断の進歩、遺伝子研究の進歩、共同研究やライセンス契約、再生医療の出現などが挙げられます。

神経疾患の罹患率の上昇が、今後数年間の神経疾患治療薬市場の成長を牽引すると予想されます。神経疾患は、脳、脊髄、神経に影響を及ぼす疾患で、構造的、生化学的、電気的な障害によって引き起こされ、さまざまな症状を引き起こします。これらの疾患の増加は、主に世界人口の高齢化と環境、代謝、ライフスタイルのリスク要因への曝露の高まりに起因しています。神経疾患治療薬は、これらの複雑な病態を管理し、症状を緩和し、病気の進行を遅らせ、患者の長期的な転帰を改善する上で極めて重要です。例えば、2024年9月、オーストラリアの政府機関であるAustralian Institute of Health and Welfareは、同国の認知症患者数が2023年の約41万1,100人から2058年には84万9,300人と2倍以上に増加し、男性31万5,500人、女性53万3,800人が罹患すると予測しています。したがって、神経疾患の有病率の増加が神経疾患治療薬市場の拡大に拍車をかけています。

神経疾患治療薬市場の主要企業は、治療効果を高め、患者の転帰を改善し、多発性硬化症患者の治療選択肢を拡大するために、革新的なオクレリズマブ薬物療法の開発に注力しています。オクレリズマブは、神経疾患である多発性硬化症（MS）の治療に用いられるヒト化モノクローナル抗体です。例えば、2024年2月、スイスの製薬会社ロシュ・ホールディングAGは、多発性硬化症の新たな疾患修飾療法（DMT）として、インドでオクレブス（Ocrelizumab）を発売しました。オクレブスは、再発寛解型多発性硬化症（RRMS）と原発性進行性多発性硬化症（PPMS）の両方に対して承認された最初で唯一のDMTであり、10年以上にわたる臨床データと実臨床データに裏付けられています。このモノクローナル抗体は、MSの中枢神経系に対する自己免疫攻撃に関与すると考えられているCD20陽性B細胞を標的とします。オクレブスはRRMSとPPMSの両方を治療し、両方の病型に対して承認された初めての薬剤となります。6ヵ月ごとに静脈内投与され、臨床試験において疾患活動性と障害の進行を抑制する有効性が示されています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界神経疾患治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の神経疾患治療薬市場：成長率分析
• 世界の神経疾患治療薬市場の実績：規模と成長, 2019-2024
• 世界の神経疾患治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界神経疾患治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の神経疾患治療薬市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• コリンエステラーゼ阻害剤
• N-メチル-D-アスパラギン酸（NMDA）受容体拮抗薬
• 抗てんかん薬
• 抗精神病薬と抗うつ薬
• その他の薬物クラス
• 世界の神経疾患治療薬市場適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• てんかん
• アルツハイマー病
• パーキンソン病
• 多発性硬化症
• 脳血管疾患
• その他の適応症
• 世界の神経疾患治療薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• その他の投与経路
• 世界の神経疾患治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• その他の流通チャネル
• 世界の神経疾患治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• ホームケア
• その他のエンドユーザー
• 世界の神経疾患治療薬市場コリンエステラーゼ阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ドネペジル
• リバスチグミン
• ガランタミン
• 世界の神経疾患治療薬市場N-メチル-D-アスパラギン酸（NMDA）受容体拮抗薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• メマンチン
• その他のNMDA受容体拮抗薬
• 世界の神経疾患治療薬市場抗てんかん薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ナトリウムチャネル遮断薬
• GABA増強剤
• グルタミン酸モジュレーター
• その他の抗てんかん薬
• 世界の神経疾患治療薬市場抗精神病薬と抗うつ薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• リスペリドン
• オランザピン
• SSRI
• SNRI
• 三環式
• 世界の神経疾患治療薬市場、その他の薬物クラスのタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ドパミン作動薬
• アルファ2作動薬
• 免疫調節薬
• その他の神経疾患治療薬

第7章 地域別・国別分析

• 世界の神経疾患治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の神経疾患治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 神経疾患治療薬市場：競合情勢
• 神経疾患治療薬市場：企業プロファイル
  • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company Pvt Ltd
• Amgen Inc.
• Boehringer Ingelheim GmbH
• Novo Nordisk A/S
• Merck KGaA
• Teva Pharmaceutical Industries Ltd.
• Otsuka America Pharmaceutical Inc.
• Biogen Inc.
• Bausch Health Companies Inc.
• Alexion Pharmaceuticals Inc.
• UCB S.A.
• Eisai Co. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 神経疾患治療薬市場2029：新たな機会を提供する国
• 神経疾患治療薬市場2029：新たな機会を提供するセグメント
• 神経疾患治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Neurological disorder drugs are medications used to treat conditions affecting the nervous system, including the brain, spinal cord, and peripheral nerves. These drugs aim to manage symptoms, slow disease progression, and improve the quality of life for individuals affected by these disorders.

The main drug classes for neurological disorders include cholinesterase inhibitors, N-Methyl-D-Aspartate (NMDA) receptor antagonists, antiepileptics, antipsychotics, antidepressants, and others. Cholinesterase inhibitors, for example, prevent the breakdown of acetylcholine, a neurotransmitter crucial for memory and cognitive function. These medications can be used for various conditions such as epilepsy, Alzheimer's disease, Parkinson's disease, multiple sclerosis, cerebrovascular disease, and others. They can be administered orally, parenterally, or by other routes. Distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and others, with end users being hospitals, specialty clinics, home care settings, and more.

The neurological disorder drugs market research report is one of a series of new reports from The Business Research Company that provides neurological disorder drugs market statistics, including neurological disorder drugs industry global market size, regional shares, competitors with a neurological disorder drugs market share, detailed neurological disorder drugs market segments, market trends and opportunities, and any further data you may need to thrive in the neurological disorder drugs industry. This neurological disorder drugs market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The neurological disorder drugs market size has grown strongly in recent years. It will grow from $84.6 billion in 2024 to $90.09 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to increasing animal testing and obtaining promising results, an increase in therapeutic treatments, the growth of neurological problems, government initiatives, and a growth in healthcare expenditure.

The neurological disorder drugs market size is expected to see strong growth in the next few years. It will grow to $114.65 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to expanding therapeutic options and personalized therapies, a growing focus on disease-modifying treatments, the expanding use of digital biomarkers, and the increasing prevalence of neurological diseases. Major trends in the forecast period include advancements in drug design, advancements in neuroimaging, advancements in genetic research, collaborations and licensing agreements, and the emergence of regenerative medicine.

The rising incidence of neurological diseases is expected to drive the growth of the neurological disorder drugs market in the coming years. Neurological disorders are conditions that affect the brain, spinal cord, and nerves, caused by structural, biochemical, or electrical disruptions, leading to various symptoms. The increase in these diseases is mainly attributed to an aging global population and heightened exposure to environmental, metabolic, and lifestyle risk factors. Drugs for neurological disorders are crucial in managing these complex conditions, providing symptom relief, slowing disease progression, and improving long-term patient outcomes. For example, in September 2024, the Australian Institute of Health and Welfare, a government agency based in Australia, projected that the number of individuals living with dementia in the country will more than double from approximately 411,100 in 2023 to 849,300 by 2058, with an estimated 315,500 men and 533,800 women affected. Therefore, the growing prevalence of neurological diseases is fueling the expansion of the neurological disorder drugs market.

Major companies in the neurological disorder drugs market are focusing on developing innovative Ocrelizumab drug therapies to enhance treatment efficacy, improve patient outcomes, and expand therapeutic options for multiple sclerosis patients. Ocrelizumab is a humanized monoclonal antibody used to treat multiple sclerosis (MS), a neurological disorder. For instance, in February 2024, Roche Holding AG, a Swiss pharmaceutical company, launched Ocrevus (Ocrelizumab) in India as a new disease-modifying therapy (DMT) for multiple sclerosis. Ocrevus is the first and only approved DMT for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS), backed by over ten years of clinical and real-world data. This monoclonal antibody targets CD20-positive B cells, believed to play a role in the autoimmune attack on the central nervous system in MS. Ocrevus treats both RRMS and PPMS, making it the first drug approved for both forms of the disease. It is administered intravenously every six months and has shown efficacy in reducing disease activity and disability progression in clinical trials.

In October 2022, Pfizer Inc., a US-based pharmaceutical company, acquired Biohaven Pharmaceuticals for $11.6 billion. This acquisition aims to bolster Pfizer's innovative internal medicine pipeline and global reach in migraine treatments by acquiring Biohaven's breakthrough calcitonin gene-related peptide portfolio, including the approved NURTEC ODT and pipeline assets such as Zavegepant. Pfizer plans to deliver these innovative therapies to over one billion people worldwide affected by migraines. Biohaven Pharmaceutical is a US-based clinical-stage biopharmaceutical company that offers a range of neurological and neuropsychiatric disorder drugs.

Major companies operating in the neurological disorder drugs market are F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Novo Nordisk A/S, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc, BioMarin Pharmaceutical Inc., Biocon Ltd, Acorda Therapeutics Inc.

North America was the largest region in the neurological disorder drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the neurological disorder drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neurological disorder drugs market consists of sales of antiepileptic drugs, dopaminergic agents, cholinesterase inhibitors, immunomodulatory drugs, and antipsychotic drugs. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neurological Disorder Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neurological disorder drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neurological disorder drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neurological disorder drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Cholinesterase Inhibitors; N-Methyl-D-Aspartate (NMDA) Receptor Antagonists; Antiepileptic; Antipsychotic And Antidepressant; Other Drugs Classes
• 2) By Indication: Epilepsy; Alzheimer's Disease; Parkinson's Disease; Multiple Sclerosis; Cerebrovascular Disease; Other Indications
• 3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
• 5) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End Users
• Subsegtments:
• 1) By Cholinesterase Inhibitors: Donepezil; Rivastigmine; Galantamine
• 2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine; Other NMDA Receptor Antagonists
• 3) By Antiepileptic: Sodium Channel Blockers; GABA Enhancers; Glutamate Modulators; Other Antiepileptics
• 4) By Antipsychotic and Antidepressant: Risperidone; Olanzapine; SSRIs; SNRIs; Tricyclic
• 5) By Other Drug Classes: Dopaminergic Drugs; Alpha-2 Agonists; Immunomodulators; Other Neurological Disorder Medications
• Companies Mentioned: F. Hoffmann-La Roche Ltd; Bayer AG; Sanofi S.A; AstraZeneca PLC; Abbott Laboratories
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Neurological Disorder Drugs Market Characteristics

3. Neurological Disorder Drugs Market Trends And Strategies

4. Neurological Disorder Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Neurological Disorder Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Neurological Disorder Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Neurological Disorder Drugs Market Growth Rate Analysis
• 5.4. Global Neurological Disorder Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Neurological Disorder Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Neurological Disorder Drugs Total Addressable Market (TAM)

6. Neurological Disorder Drugs Market Segmentation

• 6.1. Global Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cholinesterase Inhibitors
• N-Methyl-D-Aspartate (NMDA) Receptor Antagonists
• Antiepileptic
• Antipsychotic And Antidepressant
• Other Drugs Classes
• 6.2. Global Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Epilepsy
• Alzheimer's Disease
• Parkinson's Disease
• Multiple Sclerosis
• Cerebrovascular Disease
• Other Indications
• 6.3. Global Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Routes Of Administration
• 6.4. Global Neurological Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Other Distribution Channels
• 6.5. Global Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• Other End Users
• 6.6. Global Neurological Disorder Drugs Market, Sub-Segmentation Of Cholinesterase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Donepezil
• Rivastigmine
• Galantamine
• 6.7. Global Neurological Disorder Drugs Market, Sub-Segmentation Of N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Memantine
• Other NMDA Receptor Antagonists
• 6.8. Global Neurological Disorder Drugs Market, Sub-Segmentation Of Antiepileptic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sodium Channel Blockers
• GABA Enhancers
• Glutamate Modulators
• Other Antiepileptics
• 6.9. Global Neurological Disorder Drugs Market, Sub-Segmentation Of Antipsychotic and Antidepressant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Risperidone
• Olanzapine
• SSRIs
• SNRIs
• Tricyclic
• 6.10. Global Neurological Disorder Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dopaminergic Drugs
• Alpha-2 Agonists
• Immunomodulators
• Other Neurological Disorder Medications

7. Neurological Disorder Drugs Market Regional And Country Analysis

• 7.1. Global Neurological Disorder Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Neurological Disorder Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Neurological Disorder Drugs Market

• 8.1. Asia-Pacific Neurological Disorder Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Neurological Disorder Drugs Market

• 9.1. China Neurological Disorder Drugs Market Overview
• 9.2. China Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Neurological Disorder Drugs Market

• 10.1. India Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Neurological Disorder Drugs Market

• 11.1. Japan Neurological Disorder Drugs Market Overview
• 11.2. Japan Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Neurological Disorder Drugs Market

• 12.1. Australia Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Neurological Disorder Drugs Market

• 13.1. Indonesia Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Neurological Disorder Drugs Market

• 14.1. South Korea Neurological Disorder Drugs Market Overview
• 14.2. South Korea Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Neurological Disorder Drugs Market

• 15.1. Western Europe Neurological Disorder Drugs Market Overview
• 15.2. Western Europe Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Neurological Disorder Drugs Market

• 16.1. UK Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Neurological Disorder Drugs Market

• 17.1. Germany Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Neurological Disorder Drugs Market

• 18.1. France Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Neurological Disorder Drugs Market

• 19.1. Italy Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Neurological Disorder Drugs Market

• 20.1. Spain Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neurological Disorder Drugs Market

• 21.1. Eastern Europe Neurological Disorder Drugs Market Overview
• 21.2. Eastern Europe Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Neurological Disorder Drugs Market

• 22.1. Russia Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Neurological Disorder Drugs Market

• 23.1. North America Neurological Disorder Drugs Market Overview
• 23.2. North America Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Neurological Disorder Drugs Market

• 24.1. USA Neurological Disorder Drugs Market Overview
• 24.2. USA Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Neurological Disorder Drugs Market

• 25.1. Canada Neurological Disorder Drugs Market Overview
• 25.2. Canada Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Neurological Disorder Drugs Market

• 26.1. South America Neurological Disorder Drugs Market Overview
• 26.2. South America Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Neurological Disorder Drugs Market

• 27.1. Brazil Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Neurological Disorder Drugs Market

• 28.1. Middle East Neurological Disorder Drugs Market Overview
• 28.2. Middle East Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Neurological Disorder Drugs Market

• 29.1. Africa Neurological Disorder Drugs Market Overview
• 29.2. Africa Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Neurological Disorder Drugs Market Competitive Landscape And Company Profiles

• 30.1. Neurological Disorder Drugs Market Competitive Landscape
• 30.2. Neurological Disorder Drugs Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis

31. Neurological Disorder Drugs Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. GlaxoSmithKline plc
• 31.3. Takeda Pharmaceutical Company Limited
• 31.4. Eli Lilly and Company Pvt Ltd
• 31.5. Amgen Inc.
• 31.6. Boehringer Ingelheim GmbH
• 31.7. Novo Nordisk A/S
• 31.8. Merck KGaA
• 31.9. Teva Pharmaceutical Industries Ltd.
• 31.10. Otsuka America Pharmaceutical Inc.
• 31.11. Biogen Inc.
• 31.12. Bausch Health Companies Inc.
• 31.13. Alexion Pharmaceuticals Inc.
• 31.14. UCB S.A.
• 31.15. Eisai Co. Ltd.

32. Global Neurological Disorder Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neurological Disorder Drugs Market

34. Recent Developments In The Neurological Disorder Drugs Market

35. Neurological Disorder Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Neurological Disorder Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Neurological Disorder Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Neurological Disorder Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer